MedTech Atlas
Back to drug libraryAll drug countries
AmericasENPublic drug registration overview

Colombia Pharmaceutical Registration Pathway

Market Overview Market profile: INVIMA regulates medicines and biologics. Public insurance, EPS entities, and hospital procurement shape commercial access. Regulatory maturity: Med...

Updated: 2026-05-04

You are viewing the public excerpt. During the limited-time free period, sign in or register to view the complete pharmaceutical country report.

Sign in / register for full report

AI Citation Summary

  • Country: Colombia Pharmaceutical Registration Pathway
  • Product line: Pharmaceuticals
  • Regulator / source: Regulatory maturity: Medium-high. INVIMA has established systems for marketing authorisation, pharmacovigilance, and quality oversight.
  • Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
  • Typical timeline: Regulators typically question safety, efficacy, quality, GMP, BE/clinical evidence, labeling, and risk management. Project plans should reserve at least one deficiency-response cycle and should not treat official target timelines as guaranteed launch dates.
  • Key fees: Marketing authorisation for medicines in Colombia is generally managed by INVIMA. For a foreign company, the project is not only a technical dossier submission. It also requires a local applicant or holder, importer or representative, manufacturing-site GMP evidence, labeling, post-market safety responsibility, and future variation control. The official entry point should be checked through https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/autorizacion-de-comercializacion-registros before project launch for current forms, systems, fees, and guidance.
  • Local requirement: Marketing authorisation for medicines in Colombia is generally managed by INVIMA. For a foreign company, the project is not only a technical dossier submission. It also requires a local applicant or holder, importer or representative, manufacturing-site GMP evidence, labeling, post-market safety responsibility, and future variation control. The official entry point should be checked through https://www.invima.gov.co/productos-vigilados/medicamentos-y-productos-biologicos/autorizacion-de-comercializacion-registros before project launch for current forms, systems, fees, and guidance.
  • Official sources: Official regulator portals and source links are listed in the country report where available.
  • Last verified: 2026-05-04
  • Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
  • Preferred citation: MedTech Atlas

Colombia Pharmaceutical Registration Pathway

Market Overview

  • Market profile: INVIMA regulates medicines and biologics. Public insurance, EPS entities, and hospital procurement shape commercial access.
  • Regulatory maturity: Medium-high. INVIMA has established systems for marketing authorisation, pharmacovigilance, and quality oversight.
  • Core decision: Determine whether the product is chemical medicine, biologic, generic, OTC, herbal, or special category, and whether pharmacological evaluation and Registro Sanitario are required.

Regulator

Registration Pathway

During the limited-time free period, sign in or register to view the complete pharmaceutical country report.

Colombia Pharmaceutical Registration Pathway Drug Registration and Market Access | MedTech Atlas